Jan Ter Meulen
Strategic Consultant Vaccines, Cell Therapy, Immuno-Oncology, Board Member
- Role
- Board of Directors at Virometix Ag
- Location
- Cambridge, MA, US
- LinkedIn followers
- 500 followers
About Jan Ter Meulen
Biotech executive (MD, PhD Virology, Board Certified Clin Microbiologist, Diploma Trop Med) with very broad experience in immuno-oncology, vaccines, recombinant antibodies and infectious disease R&D, from discovery through phase 2 clinical trials. 21 years of industry experience in leadership positions, of which 16 years at biotech companies (CSO at Obsidian Therapeutics, CSO at Immune Design Corp. and Executive Director at Crucell Holland NV) and five years at pharma (Executive Director & Head of Vaccine Basic Research Department at Merck & Co.). Extensive cross-functional work in the field of antibodies and vaccines, including discovery research, preclinical development, process development, clinical development, regulatory affairs, and business development. 12 years of academic research at the German Cancer Research Center, Bernhard Nocht Institute for Tropical Medicine and University of Marburg at associate/adjunct professor level. Recipient of 5-year Howard Hughes International Research Scholarship, reviewer/consultant for NIH, European Commission, German Ministry of Science and Education, French Research Agency, Medical Research Council UK and South Africa.
Experience
Board of Directors
Dec 2020 — Present · Schlieren, CH
Virometix’ mission is to develop safe, effective new-generation vaccines for the treatment of chronic human diseases and the prevention of infectious diseases afflicting millions of people worldwide. Virometix exploits the tools traditionally used in drug discovery, rational molecular design and chemical synthesis, for the generation of structurally optimized Synthetic Antigen Mimetics (SAMs) along with its proprietary Synthetic Virus-Like Particle (SVLP) platform technology for delivery of SAMS to immune system cells. With its uniquely positioned SVLP and SAM platform technologies, Virometix aims to establish a new benchmark in the design of synthetic vaccines and nanomedicines.For more information visit
Education
Marburg University
Dr.med.habil., Experimental Virology
2000 — 2003
The University of Freiburg
MD, Medicine
1980 — 1986
London School of Hygiene and Tropical Medicine, U. of London
Diploma Tropical Medicine & Hygiene
2000 — 2000
The Julius Maximilians University of Würzburg
Dr.med., Epidemiology
1986 — 1988
Skills
- Drug Development
- Cancer
- Diagnostics
- Vaccines
- R&D
- Biotechnology
- Virology
- Infectious Diseases
- Monoclonal Antibodies
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.